India · Delayed Price · Currency is INR Biocon Earnings Call Transcripts
Fiscal Year 2026
-
Q4 FY 2026 saw strong revenue and margin growth, driven by biosimilars and successful business integration. Focus shifts to execution, margin expansion, and de-leveraging, with no major CapEx planned and new product launches expected to drive growth in FY 2027.
-
Q3 FY26 saw 9% YoY revenue growth, margin expansion, and strong biosimilars and generics performance, while debt was reduced and CapEx moderated. New launches and integration of Biocon Biologics position the group for sustainable growth and improved profitability.
-
Q2 FY26 saw 20% revenue growth, margin expansion, and strong biosimilars and generics performance. Debt reduction initiatives are improving profitability, with further gains expected as new launches and cost savings materialize.
-
Strong Q1 FY26 performance with 15% YoY revenue growth, led by biosimilars and CRDMO. Major product launches, capacity expansions, and a successful INR 4,500 crore QIP strengthen financials and support future growth. Interest costs set to decline as debt is repaid.
Fiscal Year 2025
-
Strong revenue and EBITDA growth driven by new launches in generics and biosimilars, with robust market access and stable pricing in key U.S. products. Improved working capital and planned capital raise position the group for further expansion and innovation.
-
Third-quarter results showed 10% year-on-year revenue growth, led by biosimilars and research services, with strong U.S. market share gains and new product launches ahead. All major manufacturing sites cleared FDA inspections, and the company completed key acquisition milestones and expanded its stake in Biocon Biologics.
-
Group revenue was flat year-on-year but grew 7% on an adjusted basis, with biosimilars delivering strong growth and generics under pressure. Successful debt refinancing improved liquidity, and the outlook for H2 FY25 is positive, driven by new launches and cost improvements.
-
Group revenue rose 30% year-on-year, driven by the Eris Lifesciences transfer, while biosimilars delivered strong growth and generics and Syngene saw declines. Regulatory progress and new launches, especially in GLP-1 and biosimilars, are set to drive H2 acceleration.